Dr. Marion Dorsch is the Chief Scientific Officer of Blueprint Medicines, a company focused on targeting genetic drivers of disease with highly selective kinase medicines. Marion has over 20 years of experience in the biopharmaceutical industry with a strong track record of discovering and advancing innovative therapies to patients. She joined Blueprint Medicines from Agios Pharmaceuticals, Inc. where she served as Vice President of Biology and contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials, two of which were recently approved in relapsed/refractory AML (IDHIFA and TIBSOVO). Prior to joining Agios, Marion was the Director of Cancer Biology at Sanofi Oncology, where she oversaw drug discovery efforts. Earlier in her career, Marion served as research project leader for the Hedgehog pathway inhibitor sonidegib (ODOMZO), now approved in the U.S. and EU for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and also worked in Inflammation Drug Discovery at Millennium Pharmaceuticals. Marion received her Ph.D. in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow at Columbia University in New York.